NCT06033170尚未招募不适用
Prospective, Single-Arm Confirmatory Clinical Investigation to Demonstrate the Effectiveness, Performance, and Safety of the Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Medtrade
- 入组人数
- 96
- 主要终点
- Celox™ PPH in controlling uterine bleeding in postpartum hemorrhage (PPH).
研究概览
简要总结
This is a post market prospective, single arm clinical investigation to continuously assess the safety performance and effectiveness of the Celox™ PPH as a uterine haemostatic tamponade treatment for uterine postpartum hemorrhage (PPH).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation
- •Female Adult subjects (>18 years of age).
- •Diagnosis of PPH with suspected uterine atony placental bed bleeding, placenta accreta or previa within 24 hours after vaginal delivery.
- •Subjects with coagulation disorders can be included
- •Minimal Estimated Blood Loss (EBL), to be determined when investigator is ready to have the Celox™ PPH package opened. 500 ml of EBL for vaginal delivery or 1000 ml for caesarean section.
- •Failed first-line intervention of uterotonics and uterine massage/bimanual compression to stop bleeding. Note: Uterotonic administration may continue concomitant with and post the Celox™ PPH use.
- •Subjects with PPH of cervical or vaginal origin.
排除标准
- •Subjects who present with, uterine rupture or for any other conditions outside of atonic post-partum haemorrhage needing other interventional methods or surgery including uterine artery embolization (UAE).
- •Pregnancy or incomplete multiple pregnancy
- •Unresolved uterine inversion.
- •Current cervical cancer.
- •Current purulent infection of the vagina, cervix, uterus.
- •Planned c-section with closed cervix.
- •Patients requiring trans-abdominal insertion of Celox™ PPH.
结局指标
主要结局
Celox™ PPH in controlling uterine bleeding in postpartum hemorrhage (PPH).
时间窗: Successful haemostasis is defined as absence of additional surgical or non-surgical interventions after application of Celox PPH. It is expected that within 2-5 minutes of application, the bleeding will be controlled.
The rate of patients in whom bleeding is controlled successfully.
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult SubjectsHemorrhageNCT03762200Ethicon, Inc.103
已完成
不适用
A Clinical Investigation With Epaderm® CreamEczemaPsoriasisDry Skin EczemaNCT03738163Molnlycke Health Care AB121
已完成
不适用
Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence ProductsUrinary IncontinenceNCT04846270Essity Hygiene and Health AB35
终止
不适用
The Pristine Post-Market StudyHemodialysis ComplicationHemodialysis Catheter InfectionHemodialysis Access FailureCentral Venous Catheter Related Bloodstream InfectionEnd Stage Renal DiseaseKidney Failure, ChronicNCT05228132C. R. Bard142
已完成
不适用
Hemoclin Gel for the Treatment of HemorrhoidsHemorrhoids Grade I and IINCT05124379Karo Pharma AB49